Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2014-07-11

FDA Approved: TRUVADA — Supplemental Application (Gilead Sciences, Inc)

View source ↗

Summary

The FDA approved a supplemental application for TRUVADA (emtricitabine/tenofovir disoproxil fumarate) to update/expand its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

SUPPL AP for TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)